UP!

Q reports

Period Date Adjusted Actuals EPS GAAP EPS
Q4 2020 2021-02-21 Future report Set alerts
Q3 2020 2020-10-25 Future report Set alerts
Q2 2020 2020-07-30 -0.54 -0.54
Q1 2020 2020-05-07 0.24 0.40
Q4 2019 2020-02-20 0.28 0.28
Q3 2019 2019-10-24 0.64 0.64
Q2 2019 2019-07-24 0.68 0.67
Q1 2019 2019-05-02 0.31 0.31
Q4 2018 2019-02-21 0.54 0.54
Q3 2018 2018-10-24 0.53 0.53

Ratings

2016-04-27 Downgrade Northland Securities Outperform to Market Perform
2016-02-26 Boost Price Target Barrington Research Outperform $45.00 to $49.00
2016-02-26 Lower Price Target Northland Securities Outperform $57.00 to $50.00
2015-10-30 Boost Price Target Barrington Research $39.00 to $45.00
2015-10-12 Initiated Coverage Barrington Research Outperform $39.00
2015-08-27 Initiated Coverage First Analysis Equal to Equal Weight
2015-07-30 Boost Price Target Northland Securities Outperform $56.00 to $57.00
2015-05-14 Initiated Coverage Northland Securities Outperform $56.00
2014-11-12 Lower Price Target Singular Research BUY to Buy $51.50 to $45.50
2014-08-19 Downgrade Singular Research Buy to BUY - Long-Term $54 to $51.50
2014-05-28 Boost Price Target Singular Research Buy $43.50 to $54.00
2014-04-08 Boost Price Target Singular Research Buy $35.00 to $43.50
2014-02-26 Reiterated Summer Street Research Buy $47 to $60
2014-02-26 Boost Price Target Summer Street Buy $47.00 to $60.00
2013-11-01 Boost Price Target Summer Street Buy $28.00 to $35.00
2013-08-02 Reiterated Summer Street Research Buy $20 to $28
2007-11-07 Reiterated Nollenberger Capital Buy $23 to $18
2007-05-08 Initiated Susquehanna Financial Neutral
2016-04-27 Downgrade Northland Securities Outperform to Market Perform
2016-02-26 Boost Price Target Barrington Research Outperform $45.00 to $49.00
2016-02-26 Lower Price Target Northland Securities Outperform $57.00 to $50.00
2015-10-30 Boost Price Target Barrington Research $39.00 to $45.00
2015-10-12 Initiated Coverage Barrington Research Outperform $39.00

There is presents forecasts of rating agencies and recommendations for investors about this ticker

Major Shareholders

Name Relationship Total Shares Holding stocks
Fidia Farmaceutici S.p.A. 4.91%  (711192) ANIK /
SHERWOOD CHARLES H President & CEO 1.31%  (189891) ANIK /
DAVIDSON EUGENE A 0.50%  (71763) ANIK /
BOWER JOSEPH I 0.28%  (41162) ANIK /
Cheung Sylvia CFO 0.26%  (37725) ANIK /
WHEELER STEVE E 0.24%  (34594) ANIK / HF /
QUINLAN KEVIN W Chief Financial Officer 0.19%  (27112) ANIK /
Hague Richard Chief Commercial Officer 0.16%  (23650) ANIK /
Darling Joseph G President 0.15%  (21436) ANIK / CNMD /
LAND RAYMOND J 0.10%  (15150) ANIK / BIOA /
Moran John C 0.10%  (14803) ANIK /
SHEETS JOHN W JR Chief Scientific Officer 0.07%  (10000) ANIK /
Larsen Glenn R. 0.06%  (8103) ANIK /
Thompson Jeffery S 0.05%  (7843) ANIK /
Ahn Edward S. Chief Tech. & Strategy Officer 0.05%  (7260) ANIK /
Mrachek William Vice President, Human Resource 0.05%  (6854) ANIK /
Finnerty Thomas Chief Human Resources Officer 0.05%  (6800) ANIK /
BARNETT CAROL A Chief Commercial Officer 0.04%  (6100) ANIK /
LUPPINO FRANCESCO J Chief Operating Officer 0.04%  (5979) ANIK /

Comments